This company listing is no longer active
ILMN.V Stock Overview
Offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Illumina, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$107.25 |
| 52 Week High | US$107.25 |
| 52 Week Low | US$107.00 |
| Beta | 1.2 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| ILMN.V | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 2.6% |
| 1Y | n/a | 14.0% | 30.5% |
Return vs Industry: Insufficient data to determine how ILMN.V performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how ILMN.V performed against the US Market.
Price Volatility
| ILMN.V volatility | |
|---|---|
| ILMN.V Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ILMN.V has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ILMN.V's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 10,615 | Jacob Thaysen | www.illumina.com |
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Illumina, Inc. Fundamentals Summary
| ILMN.V fundamental statistics | |
|---|---|
| Market cap | US$16.83b |
| Earnings (TTM) | -US$1.29b |
| Revenue (TTM) | US$4.49b |
3.8x
P/S Ratio-13.1x
P/E RatioIs ILMN.V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ILMN.V income statement (TTM) | |
|---|---|
| Revenue | US$4.49b |
| Cost of Revenue | US$1.54b |
| Gross Profit | US$2.95b |
| Other Expenses | US$4.24b |
| Earnings | -US$1.29b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 06, 2024
| Earnings per share (EPS) | -8.10 |
| Gross Margin | 65.72% |
| Net Profit Margin | -28.71% |
| Debt/Equity Ratio | 26.0% |
How did ILMN.V perform over the long term?
See historical performance and comparison